Glucagon News and Research

RSS

GLP-1 drugs may cut risk of leukemia and lymphoma in type 2 diabetes patients

Researchers found that GLP-1 receptor agonists (GLP-1RAs) significantly reduce the risk of several blood cancers in type 2 diabetes patients, especially compared to insulin. The study also highlights GLP-1RAs’ potential as a cancer-protective treatment, independent of glucose control.

9 Mar 2025

Naturally occurring molecule suppresses appetite and promotes weight loss

A naturally occurring molecule identified by Stanford Medicine researchers appears similar to semaglutide - also known as Ozempic - in suppressing appetite and reducing body weight.

6 Mar 2025

Carbs aren’t the hunger culprit: New research overturns belief that glycemic index drives overeating

A Cell Metabolism study finds that while high-GI meals spike insulin and glucose, they don’t increase hunger or consistently drive overeating, challenging the carbohydrate-insulin model’s central claims about obesity.

5 Mar 2025

Surgery first strategy could lead to better weight loss outcomes

Mass General Brigham researchers found that total weight loss did not increase for patients who took semaglutide before having weight loss surgery, suggesting that a surgery first strategy could lead to better outcomes.

5 Mar 2025

New study confirms GLP-1 medications are safe for mental health in diabetes

Researchers assess whether GLP-1 receptor agonists increase the risk of suicide, self-harm, or suicidal ideation in type 2 diabetes patients.

2 Mar 2025

New study identifies brain circuit key to reducing cocaine-seeking behavior

Imagine a future where the grip of cocaine use disorder can be loosened, where cravings fade, and the risk of relapse diminishes.

27 Feb 2025

Genetic study demonstrates fat-selective weight loss with GLP-1 agonist use

Diabetes and obesity have become pressing health issues worldwide. Glucagon-like peptide-1 (GLP-1) receptor agonists, a class of medications widely used in the treatment of type 2 diabetes (T2D), have shown significant effectiveness in both lowering blood sugar levels and aiding weight loss due to their unique pharmacological mechanisms.

25 Feb 2025

Can red ginseng prevent diabetes? New research uncovers its potential

Red ginseng extract powder significantly improved glycemic control in prediabetic Korean adults over 12 weeks without adverse effects. The findings suggest its potential role in diabetes prevention, though larger studies are needed.

23 Feb 2025

Unfolded protein response disruptions contribute to colorectal cancer and gut-related disorders

The intestinal epithelium is a highly dynamic barrier that regulates digestion, absorption, immune responses, and communication between the gut microbiota and the nervous system.

20 Feb 2025

How does intermittent fasting affect β cell function and diabetes risk

Research shows short-term fasting improves glucose regulation, while long-term fasting in young mice impairs β cell function, potentially increasing T1D risk.

18 Feb 2025

Diabetes drugs may boost brain health but experts warn of risks

Researchers reviewed 374 studies to explore how GLP-1RAs, originally for diabetes, may impact brain health, finding potential benefits for dementia and addiction but inconsistent results for mood disorders.

16 Feb 2025

Prescription trends for obesity medications surge, tied to growing interest in GLP-1 drugs

Obesity medication prescriptions reached 1.5 million, driven by GLP-1 agents semaglutide and tirzepatide, as public interest influences prescription trends.

3 Feb 2025

Gut-derived sugars: A potential game-changer for weight management and diabetes

Gut bacteria-produced exopolysaccharides (EPS) help regulate metabolism by modulating gut microbiota, promoting SCFA production, and improving glucose homeostasis. S. salivarius, a key EPS producer, shows potential for obesity and diabetes intervention.

30 Jan 2025

Revolutionizing diabetes care with innovative targets and therapeutic options

A thorough examination of modern drugs that target particular receptors and metabolic pathways for glucose and fat metabolism is presented. Recent research has revealed innovative targets and therapeutic options.

30 Jan 2025

GLP-1RA initiation linked to new thyroid cancer diagnoses

Researchers investigate the risk of incident thyroid cancer among patients treated with glucagon-like peptide-1 receptor agonists.

28 Jan 2025

What causes behavioral side effects in popular weight loss drugs?

The study of GLP1R variants shows associations with cardiometabolic traits and behavioral changes, highlighting indirect effects of GLP1RA on mental health.

23 Jan 2025

GLP1RA medications linked to behavioral side effects in type 2 diabetes and obesity

Glucagon-like peptide 1 receptor agonists (GLP1RA)-medications for type 2 diabetes and obesity that have recently been making headlines due to a rise in popularity as weight loss agents-have been linked with behavioral side effects.

22 Jan 2025

Benefits and risks of popular weight-loss drugs revealed

Demand for weight-loss medications sold under brand names such as Ozempic and Wegovy continues to surge, with a recent study reporting one in eight Americans has taken or is currently using the drugs to treat diabetes, heart disease or obesity.

20 Jan 2025

Intermuscular fat increases risk of heart disease independent of BMI

People with pockets of fat hidden inside their muscles are at a higher risk of dying or being hospitalized from a heart attack or heart failure, regardless of their body mass index, according to research published in the European Heart Journal today (Monday).

20 Jan 2025

Immune cells orchestrate glucagon production during fasting

When we think about the immune system, we usually associate it with fighting infections. However, a study published in Science by the Champalimaud Foundation reveals a surprising new role.

17 Jan 2025